Safety of ceftriaxone in paediatrics: a systematic review

Archives of Disease in Childhood
Linan ZengImti Choonara

Abstract

To determine the safety of ceftriaxone in paediatric patients and systematically evaluate the categories and incidences of adverse drug reactions (ADRs) of ceftriaxone in paediatric patients. We performed a systematic search in Medline, PubMed, Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, International Pharmaceutical Abstracts and bibliographies of relevant articles up to December 2018 for all types of studies that assessed the safety of ceftriaxone in paediatric patients aged ≤18 years. 112 studies met the inclusion criteria involving 5717 paediatric patients who received ceftriaxone and reported 1136 ADRs. The most frequent ADRs reported in prospective studies were gastrointestinal (GI) disorders (37.4 %, 292/780), followed by hepatobiliary disorders (24.6%, 192/780). Serious ADRs leading to withdrawal or discontinuation of ceftriaxone were reported in 86 paediatric patients. Immune haemolytic anaemia (34.9%, 30/86) and biliary pseudolithiasis (26.7%, 23/86) were the two major causes. Haemolytic anaemia following intravenous ceftriaxone led to death in 11 children whose primary disease was sickle cell disease. Almost all biliary pseudolithiasis are reversible. However, the incidence was high affecting one i...Continue Reading

References

Jan 18, 1990·The New England Journal of Medicine·U B SchaadJ Wedgwood
May 1, 1995·The Journal of Pediatrics·J C BerniniG R Buchanan
Feb 7, 2001·Journal of Clinical Ultrasound : JCU·A PalanduzA Somer
Dec 1, 2000·The Pediatric Infectious Disease Journal·E LeibovitzR Dagan
Dec 7, 2000·Clinical Pharmacokinetics·I Lutsar, I R Friedland
Jan 18, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Masoumeh MohkamMostafa Sharifian
Nov 30, 2011·Journal of Clinical Pharmacy and Therapeutics·G ShalviriK Gholami
Jun 13, 2012·Pediatric Reports·Takahisa KimataMinoru Kino
Aug 29, 2014·The Annals of Pharmacotherapy·Gal NeumanShinya Ito
Apr 16, 2016·Journal of Clinical Medicine Research·Qais AljfoutMohammad Saraireh
Apr 20, 2016·The Pediatric Infectious Disease Journal·Christopher R CannavinoSheldon L Kaplan
Aug 23, 2017·BMJ Open·Linan ZengMiaomiao He
Aug 24, 2017·Patient Preference and Adherence·Md Mahbubur RashidFahmida Chowdhury
Feb 14, 2018·Pediatrics·Sarah L ReevesKevin J Dombkowski
Apr 14, 2018·Evidence-based Mental Health·Orestis Efthimiou

❮ Previous
Next ❯

Citations

Jan 17, 2021·Journal of the Pediatric Infectious Diseases Society·Rebecca G SamePranita D Tamma
Jun 12, 2021·Geriatrics & Gerontology International·Takahiko Nagamine

❮ Previous
Next ❯

Software Mentioned

PRISMA
Revman

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Autoimmune Hemolytic Anemia

Autoimmune hemolytic anemia (AIHA) occurs when antibodies directed against the person's own red blood cells (RBCs) cause them to burst (lyse), leading to an insufficient number of oxygen-carrying red blood cells in the circulation. Discover the latest research on AIHA here.

Related Papers

Ugeskrift for laeger
H Friis, F Moesgaard
Indian Pediatrics
A K GuptaN K Anand
The Pediatric Infectious Disease Journal
S A Billstein, T E Sudol
Medicina clínica
J A García AlonsoC Aguirre Errasti
© 2021 Meta ULC. All rights reserved